Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07153458
Recruiting Observational

Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer

NCT07153458 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-12-01
Last updated
2025-12-19

Condition(s) studied

CRC (Colorectal Cancer)Adenoma Colon

Study summary

The study in question is an observational study that aims to identify new non-invasive biomarkers present in the serum of patients with CRC and, subsequently, to create a score capable of predicting the development of CRC.

It is an observational study with 3 enrollment arms:

Arm 1: Patients undergoing surgery at the U.O.C. of Surgery, with a CRC diagnosis;

Arm 2: Subjects with a negative result from the endoscopic examination;

Arm 3: Subjects in whom the presence of an adenoma with high-grade dysplasia is found, a condition considered pre-cancerous.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * AIM 1: Patients undergoing surgery at the U.O.C. of Surgery, with a diagnosis of CRC. * AIM 2: Subjects without colon disease. * AIM 3: Subjects with adenoma and high-grade dysplasia. Exclusion Criteria: * Subject with any other pathology not included in the inclusion criteria.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Biobank Core Facility Castellana Grotte Italy Recruiting

More Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07153458 on ClinicalTrials.gov ↗ ← All trials in Italy